<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6302">
  <stage>Registered</stage>
  <submitdate>4/10/2016</submitdate>
  <approvaldate>4/10/2016</approvaldate>
  <nctid>NCT02925117</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis</studytitle>
    <scientifictitle>A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-002451-21</secondaryid>
    <secondaryid>M16-048</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atopic Dermatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-494
Treatment: drugs - Placebo

Active Comparator: Participants receiving Dose A - Participants receiving Dose A once daily (QD) for 16 weeks

Active Comparator: Participants receiving Dose B - Participants receiving Dose B once daily (QD) for 16 weeks

Active Comparator: Participants receiving Dose C - Participants receiving Dose C once daily (QD) for 16 weeks

Placebo Comparator: Participants receiving matching placebo - Participants receiving matching placebo for 16 weeks


Treatment: drugs: ABT-494
Oral tablet

Treatment: drugs: Placebo
Oral tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean Percentage Change in EASI score - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>At Week 16</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants achieving an EASI 75 response - It is defined as at least a 75% reduction in EASI score relative to the baseline (day 1)</outcome>
      <timepoint>At Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving an Investigator Global Assessment (IGA) of "0" or "1" - The Investigators's Global Assessment (IGA) is a 5-point scale used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 (clear, no inflammatory signs of AD) to 4 (severe, Severe erythema and severe papulation/infiltration with or without oozing/crusting).</outcome>
      <timepoint>At Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in pruritus/ itch numerical rating scale (NRS) - Itch will be rated from 0 (no itch) to 10 (worst imaginable itch).</outcome>
      <timepoint>From Day 1 (Baseline) to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in EASI score - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>From Day 1 (baseline) and Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in SCORAD score - The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</outcome>
      <timepoint>From Day 1 to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving EASI 50 response - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving EASI 75 response - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving EASI 90 response - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving SCORAD 50 response - The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving SCORAD 75 response - The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants achieving SCORAD 90 response - The SCORAD is a tool used in clinical research and clinical practice that was developed to standardize the evaluation of the extent and severity of Atopic Dermatitis (AD).</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with Dermatology Life Quality Index (DLQI) = "0" or "1" - Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt;6 indicates that psoriasis has small or no effect at all on participant's life.</outcome>
      <timepoint>Up to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in DLQI - Dermatology Life Quality Index (DLQI) score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0). The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. A score &lt;6 indicates that psoriasis has small or no effect at all on participant's life.</outcome>
      <timepoint>From Day 1 to Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change and percent change from Week 16 (re-randomization) in EASI score at all Period 2 visits - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>Up to Week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to loss of EASI 50 response relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16 - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>Up to Week 88</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Summary of EASI 75 at all visits in Period 2 among those who were re-randomized as EASI 75 non-responders at Week 16 - Eczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic eczema.</outcome>
      <timepoint>Up to Week 88</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Atopic dermatitis with a diagnosis confirmed by a dermatologist (according to the
             Hanifin and Rajka criteria) and onset of symptoms at least 1 year prior to baseline.

          -  Moderate to severe atopic dermatitis defined by an Eczema Area and Severity Index
             (EASI)&gt;= 16, Body Surface Area (BSA) &gt;= 10% and an Investigators Global Assessment
             (IGA) score &gt;= 3 at the Baseline visit.

          -  Documented history (within 1 year prior to the screening visit) of inadequate response
             to treatment with topical corticosteroids (TCS), or topical calcineurin inhibitors
             (TCI), or for whom topical treatments are otherwise medically inadvisable (e.g.,
             because of important side effects or safety risks).

          -  Twice daily use of an additive-free, bland emollient for at least 7 days prior to
             Baseline.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior exposure to any systemic or topical JAK inhibitor (including but not limited to
             tofacitinib, baricitinib, ruxolitinib, and filgotinib).

          -  Treatment with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI),
             prescription moisturizers or moisturizers containing additives such as ceramide,
             hyaluronic acid, urea, or filaggrin within 10 days prior to the Baseline visit.

          -  Prior exposure to dupilumab.

          -  Prior exposure to any investigational systemic treatment within 30 days or 5
             half-lives (whichever is longer) of the Baseline visit or is currently enrolled in
             another clinical study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>30/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>167</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>25/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Skin and Cancer Foundation /ID# 157906 - Carlton</hospital>
    <hospital>St. George Dermatology and Skin Cancer Centre /ID# 157908 - Kogarah</hospital>
    <hospital>Woden Dermatology /ID# 157907 - Phillip</hospital>
    <hospital>Westmead Hospital /ID# 157905 - Westmead</hospital>
    <hospital>Veracity Clinical Research Pty Ltd /ID# 157909 - Woolloongabba</hospital>
    <postcode>3053 - Carlton</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2606 - Phillip</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ajax</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Markham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ottawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>St. John's</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Surrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Waterloo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Mikkeli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hanover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Obihiro-shi, Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sapporo-shi, Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen, GL</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an 88-week Phase 2b, randomized, double-blind, parallel-group, placebo-controlled
      multicenter study to evaluate the safety and efficacy of ABT-494 (upadacitinib) in adult
      subjects with moderate to severe atopic dermatitis. In Period 1, subjects will be randomized
      in a 1:1:1:1 ratio to one of four treatment groups.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02925117</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lynnette Richardson</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>